[{"data": {"name": "A Phase 3 Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol after 1 Year of Therapy in Early Rheumatoid Arthritis Patients", "@type": "ScholarlyArticle", "genre": "journal-article", "author": [{"name": "Michael E. Weinblatt", "@type": "Person"}, {"name": "Clifton O. Bingham", "@type": "Person"}, {"name": "Gerd-R\u00fcdiger Burmester", "@type": "Person"}, {"name": "Vivian P. Bykerk", "@type": "Person"}, {"name": "Daniel E. Furst", "@type": "Person"}, {"name": "Xavier Mariette", "@type": "Person"}, {"name": "D\u00e9sir\u00e9e van der Heijde", "@type": "Person"}, {"name": "Ronald van Vollenhoven", "@type": "Person"}, {"name": "Brenda Van Lunen", "@type": "Person"}, {"name": "C\u00e9cile Ecoffet", "@type": "Person"}, {"name": "Christopher Cioffi", "@type": "Person"}, {"name": "Paul Emery", "@type": "Person"}], "license": "cc-by-nc-nd", "@context": "http://schema.org/", "encoding": [{"@type": "MediaObject", "contentUrl": "http://europepmc.org/articles/pmc5656933?pdf=render", "encodingFormat": "application/pdf"}], "publisher": {"name": "Wiley-Blackwell", "@type": "Organization"}, "identifier": [{"@type": "PropertyValue", "value": "10.1002/art.40196", "propertyID": "DOI"}, {"@type": "PropertyValue", "value": "CCM5EBrooTs9v-CTPPKCW3xUYQ1-CDF53GvQGscQA-CRAYnVqAJoN3P", "propertyID": "ISCC"}], "datePublished": "2017-06-30"}, "schema": "schema.org", "mediatype": "application/ld+json"}]